跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 181 条关于
“SYNGAP”
全部
181
临床试验
88
药物
45
机构
6
资讯
42
11个月前
CAMP4 Therapeutics Advances SYNGAP1 Gene Therapy Toward Clinical Testing with GLP Toxicology Studies
去年
CAMP4 Therapeutics Secures $100 Million Financing to Advance First-in-Class SYNGAP1 Treatment
11个月前
Gene Therapy Shows Promise for SYNGAP1-Related Brain Disorders in Preclinical Study
去年
Stoke Therapeutics Advances Dravet Syndrome Treatment with Zorevunersen
去年
Neuren Pharmaceuticals Reports Record DAYBUE Royalties as Rett Syndrome Therapy Sales Exceed $100 Million Quarterly Milestone
3个月前
Texas Children's and Baylor Awarded Up to $17.25 Million to Join ARIA IMPACT Network for Autism Clinical Trials
10个月前
Stoke Therapeutics Advances Phase 3 Dravet Syndrome Trial with Strong Financial Position Through 2028
2年前
Syndax Pharmaceuticals Announces Key Updates and 2024 Milestones
去年
Syndax Anticipates Key Data Readouts and FDA Decision for Revumenib
去年
Syndax Pharmaceuticals' Niktimvo Approved for cGVHD, Revumenib Awaits FDA Decision
第 1 页,共 5 页
上一页
下一页